FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2591881452> ?p ?o ?g. }

• W2591881452 abstract "Abstract Abstract 2852 Background: The 18-item Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF, Scherber et al Blood 2011) given in conjunction with the 9-item Brief Fatigue Inventory (BFI, Mendoza et al Cancer 1999) is a patient-completed questionnaire for assessing symptoms in persons with MPNs. The MPN-SAF has been translated and validated in 9 languages to date. The Total Symptom Score (TSS) is computed from 10 of the most pertinent MPN-SAF items to assess symptom burden in MPN patients and to evaluate response to therapy. Psychometric properties of the TSS have been previously reported (Emanuel et al Blood 2012). The purpose of this analysis is to compare MPN-SAF symptoms and psychometric properties of the TSS across 9 languages in an international sample. Methods: Data were collected in an international cohort of subjects with MPNs. Surveyed symptoms included fatigue, early satiety, abdominal pain and discomfort, inactivity, headaches, concentration, dizziness, extremity tingling, insomnia, sexual problems, mood changes, cough, night sweats, pruritus, bone pain and fever on a 0 (absent) to 10 (worst imaginable) scale. TSS was computed using the published scoring algorithm on a 0 (all symptoms absent) to 100 (all symptoms worst imaginable) scale. Demographic and disease-related data including disease type, gender, and age had to be present to be included in analysis. Demographics were compared across languages groups using ANOVA and chi-squared tests. Symptoms and TSS were compared across language groups using a general linear model adjusting for disease type, age, and gender with post-hoc Tukey pairwise comparisons. Internal consistency and factor structure of the TSS were investigated overall and within language groups using Cronbach's alpha and principal-axis factoring analysis. Results: Subject Demographics and Disease Type: 1,851 subjects with polycythemia vera (PV N=655), essential thrombocythemia (ET N=769) and myelofibrosis (MF N=427; 286 primary MF, 61 PV-MF, 80 ET-MF) were prospectively enrolled and administered the MPN-SAF and BFI in 1 of 9 languages: English [UK] 55, English [US] 102, Italian 186, Swedish 114, German 112, French 457, Spanish 192, Dutch 236, and Chinese 397. Age (median 61, range, 15–94) and gender (55% F) were typical. Disease type and age varied across language groups (both p <0.001). MPN-SAF Symptoms and TSS: Symptom frequencies ranged from 19% (fever) to 88% (fatigue) overall with mean severities ranging from 0.4 (SD=1.3, fever) to 4.3 (SD=2.3, fatigue). Fatigue had the highest mean severity among all symptoms within each language group. Overall, mean TSS was 21.5 (SD=16.7) with the Swedish (mean=18.1, SD=15.2) and Dutch (mean=27.6, SD=17.1) cohorts reporting the lowest and highest unadjusted TSS means, respectively. When comparing symptom items across languages (adjusting for disease type, age, and gender), concentration and sexual problems had the most statistically significant pairwise differences (11 and 10, respectively, out of a possible 36) followed by dizziness and overall quality of life (9 each, out of a possible 36). No statistically significant pairwise differences were observed for abdominal discomfort, headache, extremity tingling, or insomnia. For the TSS, the Dutch cohort appeared to statistically significantly differ (all p <0.05) with all other languages except the English cohorts. All other TSS pairwise comparisons were not statistically significant. TSS Internal Consistency and Factor Structure: The TSS had excellent internal consistency overall (Cronbach's alpha 0.83) as well as within language groups (Cronbach's alpha 0.81–0.86). Overall factor analysis identified a single underlying construct among the 10 TSS items. Factor loadings ranged from 0.41 for fever to 0.73 for inactivity. A single factor solution was appropriate for each language group with factor loadings ranging from 0.18 to 0.85. Conclusion: This analysis suggests that the available translations of the MPN-SAF are generally acceptable for use in a broad context. The TSS demonstrated acceptable internal consistency and similar factor structure across all language groups. Most symptom and TSS comparisons between languages were not statistically significant, but for the few which differed, further studies are needed to evaluate whether these variances are due to disease-related factors or due to linguistic or cultural influences present in the cohorts. Disclosures: Kiladjian: Novartis: Honoraria, Research Funding; Celgene: Research Funding; Shire: Honoraria. Griesshammer:Shire: Honoraria. Roy:Novartis, BMS: Speakers Bureau. Harrison:Novartis: Honoraria, Research Funding, Speakers Bureau; YM Bioscience: Consultancy, Honoraria; Sanofi Aventis: Honoraria; Shire: Honoraria, Research Funding. Passamonti:Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees. Mesa:Incyte: Research Funding; Lilly: Research Funding; Sanofi: Research Funding; NS Pharma: Research Funding; YM Bioscience: Research Funding." @default.
• W2591881452 created "2017-03-16" @default.
• W2591881452 creator A5002936841 @default.
• W2591881452 creator A5006360930 @default.
• W2591881452 creator A5007454329 @default.
• W2591881452 creator A5008609620 @default.
• W2591881452 creator A5009381933 @default.
• W2591881452 creator A5009383961 @default.
• W2591881452 creator A5010092183 @default.
• W2591881452 creator A5010776860 @default.
• W2591881452 creator A5012374853 @default.
• W2591881452 creator A5013149964 @default.
• W2591881452 creator A5013314518 @default.
• W2591881452 creator A5016216479 @default.
• W2591881452 creator A5018111458 @default.
• W2591881452 creator A5020573943 @default.
• W2591881452 creator A5021124944 @default.
• W2591881452 creator A5026078021 @default.
• W2591881452 creator A5028061272 @default.
• W2591881452 creator A5031949106 @default.
• W2591881452 creator A5033034382 @default.
• W2591881452 creator A5034779401 @default.
• W2591881452 creator A5036322035 @default.
• W2591881452 creator A5039057642 @default.
• W2591881452 creator A5039583444 @default.
• W2591881452 creator A5042552477 @default.
• W2591881452 creator A5046436694 @default.
• W2591881452 creator A5046469980 @default.
• W2591881452 creator A5046772202 @default.
• W2591881452 creator A5046827092 @default.
• W2591881452 creator A5050171154 @default.
• W2591881452 creator A5050197133 @default.
• W2591881452 creator A5054976477 @default.
• W2591881452 creator A5055032084 @default.
• W2591881452 creator A5055401685 @default.
• W2591881452 creator A5058909416 @default.
• W2591881452 creator A5060196258 @default.
• W2591881452 creator A5060309018 @default.
• W2591881452 creator A5064703568 @default.
• W2591881452 creator A5066308745 @default.
• W2591881452 creator A5066906876 @default.
• W2591881452 creator A5069072959 @default.
• W2591881452 creator A5070207000 @default.
• W2591881452 creator A5070758043 @default.
• W2591881452 creator A5071159965 @default.
• W2591881452 creator A5074458629 @default.
• W2591881452 creator A5075154206 @default.
• W2591881452 creator A5081564703 @default.
• W2591881452 creator A5083385949 @default.
• W2591881452 creator A5088486180 @default.
• W2591881452 creator A5089433535 @default.
• W2591881452 creator A5090009905 @default.
• W2591881452 date "2012-11-16" @default.
• W2591881452 modified "2023-09-30" @default.
• W2591881452 title "Comparison of the Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Across Nine Linguistic Translations Among an International Sample of 1,851 Myeloproliferative Neoplasm (MPN) Patients." @default.
• W2591881452 doi "https://doi.org/10.1182/blood.v120.21.2852.2852" @default.
• W2591881452 hasPublicationYear "2012" @default.
• W2591881452 type Work @default.
• W2591881452 sameAs 2591881452 @default.
• W2591881452 citedByCount "0" @default.
• W2591881452 crossrefType "journal-article" @default.
• W2591881452 hasAuthorship W2591881452A5002936841 @default.
• W2591881452 hasAuthorship W2591881452A5006360930 @default.
• W2591881452 hasAuthorship W2591881452A5007454329 @default.
• W2591881452 hasAuthorship W2591881452A5008609620 @default.
• W2591881452 hasAuthorship W2591881452A5009381933 @default.
• W2591881452 hasAuthorship W2591881452A5009383961 @default.
• W2591881452 hasAuthorship W2591881452A5010092183 @default.
• W2591881452 hasAuthorship W2591881452A5010776860 @default.
• W2591881452 hasAuthorship W2591881452A5012374853 @default.
• W2591881452 hasAuthorship W2591881452A5013149964 @default.
• W2591881452 hasAuthorship W2591881452A5013314518 @default.
• W2591881452 hasAuthorship W2591881452A5016216479 @default.
• W2591881452 hasAuthorship W2591881452A5018111458 @default.
• W2591881452 hasAuthorship W2591881452A5020573943 @default.
• W2591881452 hasAuthorship W2591881452A5021124944 @default.
• W2591881452 hasAuthorship W2591881452A5026078021 @default.
• W2591881452 hasAuthorship W2591881452A5028061272 @default.
• W2591881452 hasAuthorship W2591881452A5031949106 @default.
• W2591881452 hasAuthorship W2591881452A5033034382 @default.
• W2591881452 hasAuthorship W2591881452A5034779401 @default.
• W2591881452 hasAuthorship W2591881452A5036322035 @default.
• W2591881452 hasAuthorship W2591881452A5039057642 @default.
• W2591881452 hasAuthorship W2591881452A5039583444 @default.
• W2591881452 hasAuthorship W2591881452A5042552477 @default.
• W2591881452 hasAuthorship W2591881452A5046436694 @default.
• W2591881452 hasAuthorship W2591881452A5046469980 @default.
• W2591881452 hasAuthorship W2591881452A5046772202 @default.
• W2591881452 hasAuthorship W2591881452A5046827092 @default.
• W2591881452 hasAuthorship W2591881452A5050171154 @default.
• W2591881452 hasAuthorship W2591881452A5050197133 @default.
• W2591881452 hasAuthorship W2591881452A5054976477 @default.
• W2591881452 hasAuthorship W2591881452A5055032084 @default.
• W2591881452 hasAuthorship W2591881452A5055401685 @default.
• W2591881452 hasAuthorship W2591881452A5058909416 @default.
• W2591881452 hasAuthorship W2591881452A5060196258 @default.
• W2591881452 hasAuthorship W2591881452A5060309018 @default.
• W2591881452 hasAuthorship W2591881452A5064703568 @default.
• W2591881452 hasAuthorship W2591881452A5066308745 @default.
• W2591881452 hasAuthorship W2591881452A5066906876 @default.

• next